key: cord-0925736-wiywcdes
authors: Rotzinger, David C.; Qanadli, Salah D.
title: Should Vascular Abnormalities Be Integrated Into the Chest CT Imaging Signature of Coronavirus Disease 2019?
date: 2021-05-05
journal: Chest
DOI: 10.1016/j.chest.2020.12.049
sha: 496f6a4771e2a97fa6fd9fcbc0917fddfa982f62
doc_id: 925736
cord_uid: wiywcdes

nan

We enjoyed reading the systematic review recently published in CHEST (November 2020) by Adams et al. 1 Based on 28 studies that included 3,466 patients, the authors analyzed known CT findings and structured the disease's imaging signature. Expectedly, the most frequent pattern was ground glass opacity (81.0%), but more interesting was the high prevalence of "vascular thickening" (72.9%). Although vascular abnormalities have escaped the attention of early reports, they are described increasingly and recently gained interest regarding both pathophysiologic condition and prognosis. 2 We regret that this review did not include more insights into those critical changes. In the current knowledge, vascular signs can be subdivided into two groups: thromboembolic-related abnormalities and nonthrombotic vascular changes. We believe that both should receive more attention, be identified, and reported in coronavirus disease 2019 (COVID-19) CT imaging.

From this perspective, we are intrigued by the fact that the potential incremental value of pulmonary CT angiography was not reported in this article nor discussed as a limitation. The use of IV contrast material may not be indicated in all individuals with known or suspected COVID-19; however, simultaneous severe acute respiratory syndrome coronavirus 2 pneumonia and acute pulmonary embolism is a common association that leads to specific therapeutic decisions. 3 High incidence of thromboembolic disease is a hallmark of severe COVID-19 disease and should prompt pulmonary CT angiography in selected patients. 4 Furthermore, the role of severe acute respiratory syndrome coronavirus 2-induced inflammation and thromboembolic events has been debated extensively. 5 Additionally, we would like to comment that Adams et al 1 classified vascular abnormalities as "bronchovascular abnormalities." This classification scheme suggests two assumptions: (a) the dilated vessel is not independent of bronchial abnormalities and (b) the dilated vessel is part of the bronchovascular anatomy complex, therefore necessarily an artery. Actually, dilated vessels are mostly veins running at a distance from the bronchi. When examining Figure 5 in their article, the dilated vessel is more likely to be a vein. The connection of the dilated vein with the left atrium is better seen on adjusted multiplanar reformation, as shown in Figure 1 .

For those reasons, we believe that vascular changes are independent of bronchoalveolar damage and should be integrated into the signature of the COVID-19. Furthermore, we think that CT angiography should be considered part of the imaging findings and might have a crucial impact on the decision-making process and patient treatment. 3, 4 Henkel et al 2 speculated that the observation of enlarged pulmonary arteries might be related to an increase of parenchymal and predominantly intravascular pressure, due to severe COVID-19 pulmonary microangiopathy that affected the alveolar capillary network. The high incidence of microthrombosis was also thought to be suggestive of a possible underestimation of the vascular alterations associated with COVID-19 with the use of imaging, especially on unenhanced scans. 2 Henkel et al 2 concluded that both severe acute lung injury and vascular complications contribute to fatal outcomes. These considerations largely resonate with the excellent remarks by Rotzinger and Qanadli. 1 Nevertheless, the scientific evidence on the pathophysiologic condition and clinical relevance of vascular changes on chest CT imaging in COVID-19, besides frank pulmonary embolism, is still limited, and the interpretation of this limited evidence remains somewhat speculative. Further studies are warranted to understand the nature of vascular abnormalities seen on chest CT scans and how this can help to improve patient management and outcome.

When Two Is Better Than One

To the Editor:

We compliment the retrospective study by Narain et al 1 in CHEST (March 2021) that analyzed and compared the risk of death with different immunotherapies in patients with coronavirus disease 2019 (COVID-19) .

The findings of the study had some implications for the use of immunotherapy in this patient population. Specifically, the study found that the use of corticosteroids reduced the risk of death (hazard ratio [HR], 0.66; 95% CI, 0.57-0.76), but no survival advantage was observed with the use of tocilizumab, an IL-6 receptor monoclonal antibody (HR, 0.79; 95% CI,

Chest CT imaging signature of coronavirus disease 2019 infection: in pursuit of the scientific evidence

Lethal COVID-19: radiological-pathological correlation of the lungs

Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19